Arrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growth

Arrowhead Pharmaceuticals

04/08/2026 21:10

Overview
RNAi therapeutics developer's fiscal Q3 revenue rose sharply, beating analyst expectations
Company posted a wider net loss as operating expenses increased
Arrowhead received $25 mln upfront from Madrigal licensing deal

Outlook
Company plans to submit plozasiran sNDA before end of 2026 to expand approved indications
Arrowhead expects YOSEMITE Phase 3 trial completion in mid-2027, with regulatory filings to follow
Company sees continued commercial momentum for REDEMPLO with expanding market access and physician adoption

Result Drivers
REDEMPLO GROWTH - Co said U.S. REDEMPLO prescription volume roughly doubled in the qtr and payer coverage expanded, with new marketing authorizations in Europe and Australia
LICENSING PAYMENT - Co received $25 mln upfront from Madrigal Pharmaceuticals for ARO-PNPLA3 licensing deal

Company press release: ID:nBw8t84n1a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$75.25 mln
$54.29 mln (9 Analysts)
Q3 Loss Per Share
 
$1.36
 
Q3 Operating Expenses
 
$245.35 mln
 
Q3 Operating Income
 
-$170.09 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $100.00, about 16.3% above its August 3 closing price of $86.01

Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - Vertex Q2 revenue beats estimates on strong demand for cystic fibrosis therapies, lifts outlook
Aug 3 - Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)